Will 2025 be a tipping point to unlock innovation in pharma commercialization?

Data, tech, and Artificial Intelligence (AI) are set to revolutionize the way drugs are developed and commercialized. We’re already seeing glimpses of that potential today, as pharma companies begin to pilot and validate how these new capabilities can benefit their teams and workflows.

AI promises so much in terms of delivering greater speed, efficiencies, insights, and value. It’s exciting, but also uncertain, with many companies struggling to transform their technological investments into tangible and scalable returns.

At Inizio, we partner with clients every day as they seek to use innovative solutions to address their pain points – from deriving smart insights from vast and disparate datasets to drive their decision-making, to equipping their teams and stakeholders with the most effective tools and insights to support healthcare professionals or patients achieve optimal outcomes.

“The key to unlocking the full potential of data, tech, and AI for pharma lies in aligning technological investments with strategic requirements, building robust data ecosystems, and fostering a culture of collaboration and learning across teams. Companies that prioritize human expertise alongside innovation will not only scale faster but also create sustainable value for healthcare professionals and patients alike.”

– Mary-Kate McGarry, VP, Corporate and Global Strategy, Inizio

What will you find in this report?

Insights from industry veterans and commercialization experts on the current state of the industry.
A spotlight on key trends for 2025, featuring expert perspectives from Inizio leaders worldwide and recommendations for teams looking to stay ahead of the AI curve.